Subscribe
shutterstock-135807482-roche-1
lucarista / shutterstock.com
20 May 2021Big PharmaAlex Baldwin

Roche subsidiary sues Bluebird over ‘Spark’ TM

Roche Group’s subsidiary  Spark Therapeutics has filed a complaint against rival gene therapy company  Bluebird Bio, accusing it of infringing its ‘Spark’ trademark.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK partners with Bluebird to commercialise gene therapies
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK partners with Bluebird to commercialise gene therapies
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.

More on this story

Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.
Americas
GSK partners with Bluebird to commercialise gene therapies
3 May 2017   GSK and biotech company Bluebird Bio have entered into a licence agreement centring on Bluebird’s lentiviral vector platform.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court